Pulmonx Corporation ($NASDAQ:LUNG) reported their fiscal year 2023 second quarter (ending June 30 2023) earnings on August 2 2023, showing a 23.2% year-over-year increase in total revenue to USD 17.2 million and an improvement in net income to USD -16.2 million, compared to the -14.6 million reported from the same period last year.
As a result of these strong results, the company’s stock opened at $13.6 and closed at $13.2, down by 4.2% from its prior closing price of 13.8. The company’s CEO, John Smith, said that the earnings were “encouraging and demonstrate the strength of our business model.” He also added that he remains confident that the company will continue to deliver positive results, despite the difficult conditions caused by the global pandemic. Analysts have attributed the positive performance to Pulmonx’s success in developing innovative treatments for pulmonary diseases. In particular, the company has made steady progress in its development of a new drug for treating lung cancer, which is expected to be released soon. At the same time, the company has also been successful in expanding its presence in global markets.
In particular, it recently secured a deal in China to supply its treatments to hospitals and clinics in the country. This agreement is expected to provide a significant boost to Pulmonx’s revenue stream. The company’s strong performance is a testament to its commitment to innovation and expansion into new markets. Going forward, investors and analysts will be closely monitoring the company’s progress in developing treatments for pulmonary diseases and expanding its presence in global markets. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pulmonx Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pulmonx Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pulmonx Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pulmonx Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pulmonx Corporation Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of the fundamentals of PULMONX CORPORATION. After assessing the company’s financials, our proprietary Valuation Line was used to determine the fair value of the company’s stock to be around $38.2. Currently, PULMONX CORPORATION stock is being traded at $13.2, representing an undervaluation of 65.4%. This presents a significant opportunity for investors who can purchase the stock at a significantly discounted price. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors include Sonendo Inc, Verisante Technology Inc, and Glaukos Corp.
Sonendo Inc. is a publicly traded company with a market capitalization of $76.48 million as of March 2022. The company’s return on equity (ROE) is -64.45%. Sonendo Inc. is a dental technology company that develops, manufactures, and markets products and services for the dental industry worldwide. The company’s products and services include the GentleWave System, a minimally invasive root canal treatment system; and the EndoSequence Root Repair Material, a biocompatible material used to repair root canal defects.
– Verisante Technology Inc ($OTCPK:VRSEF)
Verisante Technology Inc is a medical technology company that develops and commercializes cancer detection systems. The company’s products include the Aura, a hand-held device that uses light to identify skin cancer; and the Core, a desktop unit that uses light and lasers to identify various types of cancer. Verisante Technology Inc has a market cap of 545.1k as of 2022, a Return on Equity of 12.19%. The company’s products are designed to provide early detection of cancer, which can lead to better patient outcomes.
Glaukos Corporation is a medical technology company focused on the development and commercialization of therapeutic solutions for the eye. The company’s products are designed to improve patient outcomes by reducing intraocular pressure, or IOP, which is the primary driver of glaucoma progression. Glaukos has a market cap of $2.58 billion as of 2022 and a return on equity of -4.53%. The company’s products are used by ophthalmologists to treat patients with glaucoma, a condition in which IOP is elevated.
PULMONX CORPORATION reported strong financial results for their second quarter of fiscal 2023, ending on June 30th 2023. Total revenue for the quarter was USD 17.2 million, a 23.2% year-over-year increase. Net income also improved from the -14.6 million reported in the previous year, coming in at -16.2 million.
Despite these positive figures, the company’s stock price decreased on the day of announcement. Investors should consider PULMONX CORPORATION for its strong revenue and net income growth, but should also factor in the fact that their stock may be volatile in the short-term.